Page 44 - ESGO - Vulvar cancer - Complete report_fxd2

Table 13. Original studies presenting data in patients treated with neoadjuvant chemotherapy

Authorreference Year N Chemotherapy regimen Nb of cycl
Aragona et al.263 2012 LAVC: N = 35
CisP + 5-FU (n = 12) or CisP + Tax (n = 6) or CisP + 3
5-FU + Tax (n = 6) or VinC + Bleo + CisP (n = 6) or
Bleo alone (n = 5)

Domingues et al.262 2010 LAVC: N = 25 A) Bleo 20 mg/m² IV d1-10 continuous infusion 3
Benedetti-Panici et al.258 1993 A) N = 10 B) Tax 100 mg/m² IV weekly
B) N = 5 C) 5-FU 750 mg/m² d1-4 continuous infusion + CisP
C) N = 10 60–80 mg/m² IV d1, weekly

LAVC: N = 21 CisP 100 mg/m² day 1 + Bleo 15 mg days 1 and 8 + Up to 3
MTX 300 mg/m² day 8 every 21 days

Durrant et al.257 1990 LAVC: N = 18 Bleo 5 mg IM d1–5 + MTX 15 mg PO d1 and 4 + Up to 4
Geisler et al.261 2006 CCNU 40 mg PO d5-7 week 1, then Bleo 5 mg IM d1
LAVC: N = 13 and 4 + MTX 15 mg PO d1 and 4 weeks 2-5
A) N = 10
B) N = 3 A) 5-FU 1,000 mg/m²/24 h infusion d1-5 + CisP 50 3-4
mg/m² IV d1, q3 weeks
B) CisP 50 mg/m² IV q3 weeks

Wagenaar et al.259 2001 LAVC: N = 12 Week 1: Bleo 5 mg IM d1-5 + CCNU 40 mg PO d5-7 Up to 3
Bafna et al.260 2004 LAVC: N = 9 + MTX 10 mg PO d1+4
Weeks 2-6: Bleo 5 mg IM d1 + 4 + MTX 15 mg PO
d1.

Cyclo 500 mg + MTX 50 mg + 5-FU 500 mg days 1, 3
8 every 14 d

Han et al.264 2012 LAVC: N = 4 Tax 60 mg/m² IV + Carbo AUC 2.7 IV weekly Up to 9

5-FU: 5-fluorouracil, Bleo: bleomycin, Carbo: carboplatin, CisP: cisplatin, CCNU: lomustine, CR: complete response, Cyclo
NED: no evidence of disease and no recurrence, ORR: overall response rate, pCR: pathologic complete response, PR: partial

 VULVAR CANCE
44